The value of infectious diseases specialists: Non-patient care activities

Clinical Infectious Diseases

Volumn 47, Issue 8, 2008, Pages 1051-1063

  McQuillen, Daniel P ^a,g   Petrak, Russell M ^b   Wasserman, Ronald B ^c   Nahass, Ronald G ^d   Scull, Jason A ^e   Martinelli, Lawrence P ^f  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Metro Infectious Diseases Consultants   (United States)

^c Infectious Diseases Medical Group   (United States)

^d ID Care   (United States)

^e Infectious Diseases Society of America Emerging Infections Network   (United States)

^f Consultants in Infectious Diseases ^*  (United States)

^g LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CHLORHEXIDINE; MINOCYCLINE; RIFAMPICIN; SULFADIAZINE SILVER;

CENTRAL VENOUS CATHETER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ENVIRONMENTAL EXPOSURE; HEALTH CARE MANAGEMENT; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH STATISTICS; HOSPITAL COST; HOSPITAL MANAGEMENT; HOSPITALIZATION; HUMAN; INFECTION; INFECTION CONTROL; INFECTION CONTROL PRACTITIONER; LENGTH OF STAY; LONGITUDINAL STUDY; MEDICAL SPECIALIST; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; WELLBEING;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; HEALTH PERSONNEL; HUMANS; INFECTION CONTROL; SPECIALISM;

EID: 53349174069     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/592067     Document Type: Review

References (102)

1. Wenzel RP. Value of the infectious diseases specialist. Clin Infect Dis 1997; 24:456.
2. Petrak RM, Sexton DJ, Butera ML, et al. The value of an infectious diseases specialist. Clin Infect Dis 2003; 36:1013-7.
3. Carling P, Fung T, Killion A, et al. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003; 24:699-706.
4. White AC Jr, Atmar RL, Wilson J, et al. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997; 25:230-9.
5. Gross R, Morgan AS, Kinky DE, et al. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis 2001; 33:289-95.
6. Bantar C, Sartori B, Vesco E, et al. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis 2003; 37:180-6.
7. Fraser GL, Stogsdill P, Dickens JD Jr, et al. Antibiotic optimization: an evaluation of patient safety and economic outcomes. Arch Intern Med 1997; 157:1689-94.
8. Stogsdill P, Claffey T, Bates P, et al. Antimicrobial stewardship program: from research to practice [abstract 583]. In: Program and abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America (Chicago, IL). Arlington, VA: Infectious Diseases Society of America, 2002:147.
9. Modjtabai K, Prato BS, Stogsdill PB, Owens RC Jr. Impact of inpatient prescribing changes on antimicrobial susceptibilities: a five-year longitudinal study [abstract 156]. In: Program and abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America (San Diego, CA). Arlington, VA: Infectious Diseases Society of America, 2003:53.
10. Srinivasan A, Patel A, Song X, et al. Cost reductions in antimicrobial expenditures following implementation of a comprehensive antimicrobial management program (AMP) [abstract 488]. In: Program and abstracts of the 41st Meeting of the Infectious Diseases Society of America (San Diego, CA). Arlington, VA: Infectious Diseases Society of America, 2003:44.
11. LaRocco A Jr. Concurrent antibiotic review programs - a role for infectious diseases specialists at small community hospitals. Clin Infect Dis 2003; 37:742-3.
12. Gentry CA, Greenfield RA, Slater LN, et al. Outcomes of an antimicrobial control program in a teaching hospital. Am J Health Syst Pharm 2000; 57:268-74.
13. Montecalvo MA, Jarvis WR, Uman J, et al. Costs and savings associated with infection control measures that reduced transmission of vancomycin-resistant Enterococci in an endemic setting. Infect Control Hosp Epidemiol 2001; 22:437-42.
14. Ozkurt Z, Erol S, Kadanali A, et al. Changes in antibiotic use, cost and consumption after an antibiotic restriction policy applied by infectious disease specialists. Jpn J Infect Dis 2005; 58:338-43.
15. Woodward RS, Medoff G, Smith MD, et al. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital. Am J Med 1987; 83:817-23.
16. Philmon C, Smith T, Williamson S, et al. Controlling use of antimicrobials in a community teaching hospital. Infect Control Hosp Epidemiol 2006; 27:239-44.
17. Lutters M, Harbarth S, Janssens JP, et al. Effect of a comprehensive, multidisciplinary, educational program on the use of antibiotics in a geriatric university hospital. J Am Geriatr Soc 2004; 52:112-6.
18. Haley RW, Culver DH, White JW, et al. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am J Epidemiol 1985; 121:182-205.
19. Monitoring hospital-acquired infections to promote patient safety - United States, 1990-1999. MMWR Morb Mortal Wkly Rep 2000; 49:149-53.
20. Roberts RR, Scott RD II, Cordell R, et al. The use of economic modeling to determine the hospital costs associated with nosocomial infections. Clin Infect Dis 2003; 36:1424-32.
21. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA 2003; 290:1868-74.
22. 2008 Medicare inpatient prospective payment system final rule, August 2007. Baltimore, MD: Centers for Medicare and Medicaid Services, 2007.
23. 2009 Medicare inpatient prospective payment system final rule, August 2008. Baltimore, MD: Centers for Medicare and Medicaid Services, 2008.
24. Slitt M. Promoting patient safety: CIGNA to stop reimbursing hospitals for never events and avoidable hospital conditions. 2008. Available at: http://newsroom.cigna.com/article_display.cfm?article_idp888. Accessed 24 June 2008.
25. Binns K. WellPoint announces initiative aimed at preventing serious medical errors. 2008. Available at: http://www.bcbs.com/news/plans/ wellpoint-announces-initiative.html. Accessed 24 June 2008.
26. Mullins J. National Quality Forum updates endorsement of serious reportable events in healthcare 2006. Available at: http://www.qualityforum.org/ pdf/news/prSeriousReportableEvents10-15-06.pdf. Accessed 24 June 2008.
27. Edwards JR, Peterson KD, Andrus ML, et al. National Healthcare Safety Network (NHSN) report, data summary for 2006, issued June 2007. Am J Infect Control 2007; 35:290-301.
28. Kaye KS, Engemann JJ, Fulmer EM, et al. Favorable impact of an infection control network on nosocomial infection rates in community hospitals. Infect Control Hosp Epidemiol 2006; 27:228-32.
29. Schramm GE, Johnson JA, Doherty JA, et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit Care Med 2006; 34:2069-74.
30. Shorr AF, Micek ST, Kollef MH. Inappropriate therapy for methicillin-resistant Staphylococcus aureus: resource utilization and cost implications. Crit Care Med 2008; 36:2335-40.
31. Kaye KS, Anderson DJ, Choi Y, et al. The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals. Clin Infect Dis 2008; 46:1568-77.
32. Jenkins TC, Price CS, Sabel AL, et al. Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:1000-8.
33. HealthGrades I. Second Annual Patient Safety in American Hospitals Report - May 2005. Available at: http://www.healthgrades.com/media/DMS/pdf/ PatientSafetyInAmericanHospitalsReportFINAL42905Post.pdf. Accessed 8 August 2008.
34. Anderson DJ, Kirkland KB, Kaye KS, et al. Underresourced hospital infection control and prevention programs: penny wise, pound foolish? Infect Control Hosp Epidemiol 2007; 28:767-73.
35. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271:1598-601.
36. Elward AM, Hollenbeak CS, Warren DK, et al. Attributable cost of nosocomial primary bloodstream infection in pediatric intensive care unit patients. Pediatrics 2005; 115:868-72.
37. Dimick JB, Pelz RK, Consunji R, et al. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg 2001; 136:229-34.
38. Digiovine B, Chenoweth C, Watts C, et al. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med 1999; 160:976-81.
39. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85.
40. Maki DG, Stolz SM, Wheeler S, et al. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: a randomized, controlled trial. Ann Intern Med 1997; 127:257-66.
41. Veenstra DL, Saint S, Saha S, et al. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA 1999; 281:261-7.
42. Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections: a randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med 1997; 127:267-74.
43. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N Engl J Med 1999; 340:1-8.
44. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006; 355:2725-32.
45. Bonten MJM. Nosocomial pneumonia. In: Mayhall CG, ed. Hospital epidemiology and infection control. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1999:211-38.
46. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903.
47. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122:2115-21.
48. Resar R, Pronovost P, Haraden C, et al. Using a bundle approach to improve ventilator care processes and reduce ventilator-associated pneumonia. Jt Comm J Qual Patient Saf 2005; 31:243-8.
49. Koeman M, van der Ven AJ, Hak E, et al. Oral decontamination with chlorhexidine reduces the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 2006; 173:1348-55.
50. Kirkland KB, Briggs JP, Trivette SL, et al. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol 1999; 20:725-30.
51. Poulsen KB, Wachmann CH, Bremmelgaard A, et al. Survival of patients with surgical wound infection: a case-control study of common surgical interventions. Br J Surg 1995; 82:208-9.
52. Hollenbeak CS, Murphy DM, Koenig S, et al. The clinical and economic impact of deep chest surgical site infections following coronary artery bypass graft surgery. Chest 2000; 118:397-402.
53. Furnary AP, Zerr KJ, Grunkemeier GL, et al. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67:352-60; discussion 60-2.
54. Whitehouse JD, Friedman ND, Kirkland KB, et al. The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: adverse quality of life, excess length of stay, and extra cost. Infect Control Hosp Epidemiol 2002; 23:183-9.
55. Levi AD, Dickman CA, Sonntag VK. Management of postoperative infections after spinal instrumentation. J Neurosurg 1997; 86:975-80.
56. Rubin RJ, Harrington CA, Poon A, et al. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 1999; 5:9-17.
57. Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother 2004; 38:1377-82.
58. Shorr AF, Tabak YP, Gupta V, et al. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care 2006; 10:R97.
59. Vonberg RP, Stamm-Balderjahn S, Hansen S, et al. How often do asymptomatic healthcare workers cause methicillin-resistant Staphylococcus aureus outbreaks? A systematic evaluation. Infect Control Hosp Epidemiol 2006; 27:1123-7.
60. Lee SY, Kotapati S, Kuti JL, et al. Impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol 2006; 27:1226-32.
61. Foglia EE, Fraser VJ, Elward AM. Effect of nosocomial infections due to antibiotic-resistant organisms on length of stay and mortality in the pediatric intensive care unit. Infect Control Hosp Epidemiol 2007; 28:299-306.
62. Kyne L, Hamel MB, Polavaram R, et al. Health care costs andmortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34:346-53.
63. Lawrence SJ, Puzniak LA, Shadel BN, et al. Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure. Infect Control Hosp Epidemiol 2007; 28:123-30.
64. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12:409-15.
65. Dubberke ER, Reske KA, Olsen MA, et al. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis 2008; 46:497-504.
66. Weber SG, Huang SS, Oriola S, et al. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force. Infect Control Hosp Epidemiol 2007; 28:249-60.
67. Shitrit P, Gottesman BS, Katzir M, et al. Active surveillance for methicillin-resistant Staphylococcus aureus (MRSA) decreases the incidence of MRSA bacteremia. Infect Control Hosp Epidemiol 2006; 27:1004-8.
68. Clancy M, Graepler A, Wilson M, et al. Active screening in high-risk units is an effective and cost-avoidant method to reduce the rate of methicillin-resistant Staphylococcus aureus infection in the hospital. Infect Control Hosp Epidemiol 2006; 27:1009-17.
69. van Trijp MJ, Melles DC, Hendriks WD, et al. Successful control of widespread methicillin-resistant Staphylococcus aureus colonization and infection in a large teaching hospital in The Netherlands. Infect Control Hosp Epidemiol 2007; 28:970-5.
70. Noskin GA, Rubin RJ, Schentag JJ, et al. Budget impact analysis of rapid screening for Staphylococcus aureus colonization among patients undergoing elective surgery in US hospitals. Infect Control Hosp Epidemiol 2008; 29:16-24.
71. Gavalda L, Masuet C, Beltran J, et al. Comparative cost of selective screening to prevent transmission of methicillin-resistant Staphylococcus aureus (MRSA), compared with the attributable costs of MRSA infection. Infect Control Hosp Epidemiol 2006; 27:1264-6.
72. Chaix C, Durand-Zaleski I, Alberti C, et al. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 1999; 282:1745-51.
73. Tambyah PA, Knasinski V, Maki DG. The direct costs of nosocomial catheter-associated urinary tract infection in the era of managed care. Infect Control Hosp Epidemiol 2002; 23:27-31.
74. Saint S. Clinical and economic consequences of nosocomial catheter-related bacteriuria. Am J Infect Control 2000; 28:68-75.
75. Riley DK, Classen DC, Stevens LE, et al. A large randomized clinical trial of a silver-impregnated urinary catheter: lack of efficacy and staphylococcal superinfection. Am J Med 1995; 98:349-56.
76. Maki DG, Tambyah PA. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis 2001; 7:342-7.
77. Johnston CP, Qiu H, Ticehurst JR, et al. Outbreak management and implications of a nosocomial norovirus outbreak. Clin Infect Dis 2007; 45:534-40.
78. Virginia International Healthcare Worker Safety Center. EPINet compendium of articles on healthcare worker safety. Available at: http://www.healthsystem. virginia.edu/internet/epinet/RefManBib.htm. Accessed 24 June 2008.
79. Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS; U.S. Public Health Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2005; 54(RR-9):1-17.
80. Perry J, Parker G, Jagger J. EPINet report: 2003 percutaneous injury rates. Virginia International Healthcare Worker Safety Center. Advances in Exposure Prevention 2005; 7:42-5. Available at: http://www.healthsystem. virginia.edu/Internet/epinet/EPINet-2003-report.pdf. Accessed 24 June 2008.
81. Green-McKenzie J, Shofer FS. Duration of time on shift before accidental blood or body fluid exposure for housestaff, nurses, and technicians. Infect Control Hosp Epidemiol 2007; 28:5-9.
82. Fisman DN, Harris AD, Rubin M, et al. Fatigue increases the risk of injury from sharp devices in medical trainees: results from a case-crossover study. Infect Control Hosp Epidemiol 2007; 28:10-7.
83. California OSHA. Initial Statement of Reasons, California Code of Regulation. Title 8: general industry safety orders. Chapter 4, subchapter 7, article 109, section 5193. Bloodborne pathogens/sharpsinjury prevention. 24 June 1999. Available at: http://www.dir.ca.gov/title8/5193.html. Accessed 26 August 2008.
84. O'Malley EM, Scott RD II, Gayle J, et al. Costs of management of occupational exposures to blood and body fluids. Infect Control Hosp Epidemiol 2007; 28:774-82.
85. Scheid DC, Hamm RM, Stevens KW. Cost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers. Pharmacoeconomics 2000; 18:355-68.
86. Azar-Cavanagh M, Burdt P, Green-McKenzie J. Effect of the introduction of an engineered sharps injury prevention device on the percutaneous injury rate in healthcare workers. Infect Control Hosp Epidemiol 2007; 28:165-70.
87. Bryant KA, Humbaugh K, Brothers K, et al. Measures to control an outbreak of pertussis in a neonatal intermediate care nursery after exposure to a healthcare worker. Infect Control Hosp Epidemiol 2006; 27:541-5.
88. Pascual FB, McCall CL, McMurtray A, et al. Outbreak of pertussis among healthcare workers in a hospital surgical unit. Infect Control Hosp Epidemiol 2006; 27:546-52.
89. Calugar A, Ortega-Sanchez IR, Tiwari T, et al. Nosocomial pertussis: costs of an outbreak and benefits of vaccinating health care workers. Clin Infect Dis 2006; 42:981-8.
90. De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000; 182:174-9.
91. Salgado CD, Giannetta ET, Hayden FG, et al. Preventing nosocomial influenza by improving the vaccine acceptance rate of clinicians. Infect Control Hosp Epidemiol 2004; 25:923-8.
92. Saxen H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J 1999; 18:779-83.
93. OSHA. Pandemic influenza preparedness and response guidance for healthcare workers and healthcare employers 2007. Available at: http://www.osha.gov/Publications/OSHA_pandemic_health.pdf. Accessed 26 August 2008.
94. Mahoney FJ, Stewart K, Hu H, et al. Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. Arch Intern Med 1997; 157:2601-5.
95. Bolyard EA, Tablan OC, Williams WW, et al. Guideline for infection control in healthcare personnel, 1998. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1998; 19:407-63.
96. Kretsinger K, Broder KR, Cortese MM, et al.; Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006; 55(RR-17):1-37.
97. Wharton M, Strikas RA, Harpaz R, et al.; Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee. Recommendations for using smallpox vaccine in a pre-event vaccination program: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003; 52(RR-7):1-16.
98. Mast EE, Weinbaum CM, Fiore AE, et al.; Advisory Committee on Immunization Practices; Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55 (RR-16):1-33; quiz CE1-4.
99. Marin M, Güris D, Chaves SS, Schmid S, Seward JF; Advisory Committee on Immunization Practices; Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56(RR-4):1-40.
100. Jensen PA, Lambert LA, Iademarco MF, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005; 54:1-141.
101. Ury W. Getting past no: negotiating your way from confrontation to cooperation. New York: Bantam Books, 1991.
102. Medicare program: physicians' referrals to health care entities with which they have financial relationships (phase III): final rule. Federal register. United States Government; Department of Health and Human Services Centers for Medicare and Medicaid Services. 2007; 72:51052-99. Available at: http://edocket.access.gpo.gov/2007/pdf/07-4252.pdf. Accessed 26 August 2008.